PTM Wealth Management LLC Makes New Investment in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• PTM Wealth Management LLC recently acquired a new stake in NewAmsterdam Pharma Company N.V., investing approximately $256,000 for 12,900 shares.
• Insider Johannes Jacob Piete Kastelein sold 50,000 shares for about $1.21 million, marking a significant reduction in ownership.
• Analysts give NewAmsterdam Pharma a consensus rating of "Moderate Buy", with a price target averaging $41.55, despite the company reporting a net margin of -259.07%.

PTM Wealth Management LLC purchased a new stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 12,900 shares of the company's stock, valued at approximately $256,000.

A number of other hedge funds have also recently made changes to their positions in the company. Quarry LP bought a new position in shares of NewAmsterdam Pharma during the first quarter worth about $25,000. GF Fund Management CO. LTD. bought a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $50,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in NewAmsterdam Pharma by 19.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after purchasing an additional 596 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in NewAmsterdam Pharma by 130.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock valued at $123,000 after acquiring an additional 3,390 shares during the period. Finally, Avanza Fonder AB acquired a new stake in NewAmsterdam Pharma in the first quarter valued at approximately $127,000. 89.89% of the stock is owned by institutional investors and hedge funds.

NewAmsterdam Pharma Stock Down 0.5%

Shares of NASDAQ:NAMS traded down $0.13 during trading on Friday, hitting $26.61. The stock had a trading volume of 157,125 shares, compared to its average volume of 886,593. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $27.35. The company has a market capitalization of $3.00 billion, a PE ratio of -16.42 and a beta of -0.01. The firm's fifty day moving average is $24.00 and its 200 day moving average is $20.93.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.The firm had revenue of $19.15 million during the quarter, compared to analyst estimates of $1.44 million. Equities research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Royal Bank Of Canada raised their price objective on NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a research note on Thursday, August 7th. Wells Fargo & Company began coverage on NewAmsterdam Pharma in a research report on Monday, August 25th. They set an "overweight" rating and a $45.00 target price on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. Cantor Fitzgerald assumed coverage on NewAmsterdam Pharma in a research report on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 price objective on the stock. Finally, The Goldman Sachs Group began coverage on NewAmsterdam Pharma in a research report on Thursday, July 17th. They issued a "neutral" rating and a $27.00 price objective on the stock. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $41.55.

Insider Buying and Selling

In related news, COO Douglas F. Kling sold 51,043 shares of NewAmsterdam Pharma stock in a transaction on Wednesday, July 16th. The stock was sold at an average price of $21.10, for a total transaction of $1,077,007.30. Following the transaction, the chief operating officer directly owned 44,000 shares in the company, valued at approximately $928,400. The trade was a 53.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James N. Topper acquired 2,520 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, June 24th. The stock was purchased at an average cost of $18.43 per share, with a total value of $46,443.60. Following the completion of the purchase, the director owned 3,024,873 shares of the company's stock, valued at approximately $55,748,409.39. This represents a 0.08% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 6,171 shares of company stock valued at $127,875 and have sold 324,954 shares valued at $7,844,906. Corporate insiders own 20.84% of the company's stock.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.